201. Development of a novel human adrenomedullin derivative: human serum albumin-conjugated adrenomedullin.
- Author
-
Kuroishi, Nobuko, Nagata, Sayaka, Akashi, Emiko, Ashizuka, Shinya, Kato, Johji, Yamasaki, Motoo, and Kitamura, Kazuo
- Subjects
ADRENOMEDULLIN ,CYCLIC adenylic acid ,PEPTIDES ,MOLECULAR weights ,GEL electrophoresis - Abstract
Adrenomedullin is a biologically active peptide with multiple functions. Here, we have developed a novel human serum albumin-adrenomedullin (HSA-AM) conjugate, which was synthesized by the covalent attachment of a maleimide derivative of adrenomedullin to the 34th cysteine residue of HSA via a linker. Denaturing gel electrophoresis and western blotting for HSA-AM yielded a single band with adrenomedullin immunoreactivity at the position corresponding to a molecular weight (MW) of 73 kDa. Following gel-filtration chromatography, the purified HSA-AM showed a single main peak corresponding with an MW of 73 kDa, indicating that HSA-AM is a monomer. Both adrenomedullin and HSA-AM stimulated the intracellular accumulation of cyclic AMP (cAMP) in HEK-293 cells stably expressing the adrenomedullin 1 receptor. The pEC
50 values for adrenomedullin and HSA-AM were 8.660 and 7.208 (equivalent to 2.19 and 61.9 nM as EC50 ), respectively. The bioavailability of HSA-AM compared with that of adrenomedullin was much improved after subcutaneous administration in the rat, which was probably due to the superior resistance of HSA-AM towards endogenous proteases and its reduced clearance from the blood. HSA-AM may be a promising drug candidate for clinical application. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF